Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edgewise Therapeutics (EWTX) Retained Earnings (2020 - 2026)

Edgewise Therapeutics has reported Retained Earnings over the past 7 years, most recently at -$252000.0 for Q1 2026.

  • Quarterly results put Retained Earnings at -$252000.0 for Q1 2026, down 162.84% from a year ago — trailing twelve months through Mar 2026 was -$252000.0 (down 162.84% YoY), and the annual figure for FY2025 was -$546.4 million, down 130188.33%.
  • Retained Earnings reached -$252000.0 in Q1 2026 per EWTX's latest filing, up from -$546.4 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $420000.0 in Q4 2024 and bottomed at -$546.4 million in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$144.6 million (2022), compared with a mean of -$172.9 million.
  • The largest annual shift saw Retained Earnings crashed 326263.64% in 2022 before it soared 119.35% in 2025.
  • Over 5 years, Retained Earnings stood at -$144.6 million in 2022, then tumbled by 69.27% to -$244.8 million in 2023, then surged by 100.17% to $420000.0 in 2024, then plummeted by 130188.33% to -$546.4 million in 2025, then skyrocketed by 99.95% to -$252000.0 in 2026.
  • Business Quant data shows Retained Earnings for EWTX at -$252000.0 in Q1 2026, -$546.4 million in Q4 2025, and -$496.2 million in Q3 2025.